Two recipients to receive cutting-edge services from EA and
"Our grant program offers motivation, encouragement and resources to researchers who share our commitment to identify genetic factors that influence health and disease," said
"We are once again pleased to join EA in providing grants to researchers to uncover novel genetic insights important to human health and the diagnosis and treatment of disease," said
The 2014 Oncology Research
Grant applications will be reviewed and scored by technical experts at EA and
About EA
EA, a Quintiles company, provides cutting-edge genomic sequencing, gene expression, genotyping, and bioinformatics services to the world's largest pharmaceutical companies, diagnostic test developers, government agencies, and academic labs. All projects are conducted under clinical-grade quality control, ensured through CLIA certification, GLP compliance, and adherence to CLSI guidelines. EA's bioinformatics staff are key contributors to the Food and Drug Administration's MicroArray Quality Control (MAQC) and Sequencing Quality Control (SEQC) studies, which aim to improve standards and quality measures for reliable use of next-generation sequencing and gene expression technologies in clinical practice and regulatory decision-making. As part of its mission to improve human health, EA has donated more than
Click here to subscribe to Mobile Alerts for Quintiles.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140819005047/en/
Source: Quintiles
Quintiles
Mari Mansfield, Corporate Communications ([email protected])
1-919-998-2639
or
Karl Deonanan, Investor Relations ([email protected])
1-919-998-2789